Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Sponsor: Afimmune
Summary
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.
Official title: An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-01-10
Completion Date
2026-03
Last Updated
2025-10-27
Healthy Volunteers
No
Conditions
Interventions
Epeleuton
Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
Locations (18)
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States
New England Sickle Cell Institute, UConn Health
Farmington, Connecticut, United States
Medstar Health
Washington D.C., District of Columbia, United States
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Hughes Spalding
Atlanta, Georgia, United States
Emory University - Georgia Comprehensive Sickle Cell Center
Atlanta, Georgia, United States
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Arthur M. Blank Hospital
Atlanta, Georgia, United States
UI Health Sickle Cell Center
Chicago, Illinois, United States
The Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders, A Division of American Oncology Partners, PA
Bethesda, Maryland, United States
Kaiser Permanente Mid-Atlantic States
Largo, Maryland, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Robert Wood Johnson Medical School Rutgers
New Brunswick, New Jersey, United States
Newark Beth Israel Medical Center
Newark, New Jersey, United States
Jacobi Medical Center
The Bronx, New York, United States
UNC Health
Chapel Hill, North Carolina, United States
Science 37
Morrisville, North Carolina, United States
St Paul's Hospital Hematology/Oncology Research
Vancouver, British Columbia, Canada
Toronto General Hospital
Toronto, Ontario, Canada